• OUTLOOK ARENA
  • VIEWS ON NEWS
  • JUNE 13, 2000

Rupee depreciation to hit SmithKline, Pfizer

The recent depreciation of the rupee is likely to hit mutinational pharmaceutical companies such as SmithKline Beecham and Pfizer quite adversely. This is primarily because imports not only account for a relatively larger proportion of their raw material cost but these companies also import a substantial amount (in terms of their raw material imports) of finished goods. (SmithKline actually imports its Hepatitis–B formulation Engerix from the Belgium plant of its parent.)

  Imports (Rs m)
Company Raw Material Finished goods
SmithKline Pharma 75.1 679.7
Pfizer 93.1 99.1

While the Indian companies such as Ranbaxy, Cipla and Dr Reddys should be net gainers of the rupee depreciation since their exports account for a decent proportion of their turnover, the fact remains that unless their exports account for value added formulations the foreign buyers usually insist on proportionate discounts (proportionate to the value of depreciation). The net impact would however be positive for these companies.

Company Exports
(Rs m)
Imports
(Rs m)
Exports / Sales Imports of
Raw Material
Ranbaxy 8,138.1 3,138.2 48.8% 48.4%
Dr Reddys 1,184.2 761.2 27.8% 46.0%
Cipla 1,163.5 5,520.4 18.9% 30.0%
Glaxo 761.9 683.4 8.6% 12.2%
SmithKline Beecham 190.6 760.5 5.9% 24.0%
Pfizer 67.0 201.8 2.0% 10.8%
German Remedies 59.0 11.9 9.8% 31.6%

There are also companies such as Glaxo and German Remedies, which import certain bulk drugs from their parents but they also serve as a sourcing base for the supply of older formulations to their parents. For instance Glaxo imports cefutoxamine (the bulk drug for Ceftum) from its parent but also supplies ranitidine to its parent. For these companies while the overall impact of the depreciation of the rupee would be negative it would be alleviated to some extent due to their exports.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407